NexgenRx Valuation
Is NEGX.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NEGX.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate NEGX.F's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NEGX.F's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NEGX.F?
Key metric: As NEGX.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is NEGX.F's PS Ratio? | |
|---|---|
| PS Ratio | 1.4x |
| Sales | CA$15.34m |
| Market Cap | CA$20.98m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.4x |
| Enterprise Value/EBITDA | 15.4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does NEGX.F's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.4x | ||
MRAI Marpai | 0.6x | n/a | US$22.0m |
MAAL Marketing Alliance | 0.6x | n/a | US$11.5m |
HUIZ Huize Holding | 0.2x | 9.1% | US$36.2m |
RELI Reliance Global Group | 0.2x | n/a | US$2.5m |
NEGX.F NexgenRx | 1.4x | n/a | US$21.0m |
Price-To-Sales vs Peers: NEGX.F is expensive based on its Price-To-Sales Ratio (1.4x) compared to the peer average (0.4x).
Price to Sales Ratio vs Industry
How does NEGX.F's PS Ratio compare vs other companies in the US Insurance Industry?
Price-To-Sales vs Industry: NEGX.F is expensive based on its Price-To-Sales Ratio (1.4x) compared to the US Insurance industry average (1.1x).
Price to Sales Ratio vs Fair Ratio
What is NEGX.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.4x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate NEGX.F's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Sompo Holdings
JP¥3.4t
Provides property and casualty (P&C) insurance services in Japan and internationally.
SMPN.Y
JP¥11.32
7D
-0.4%
1Y
55.5%
American Financial Group
US$11.6b
An insurance holding company, provides specialty property and casualty insurance products in the United States.
AFG
US$139.64
7D
-1.8%
1Y
28.1%
Fairfax Financial Holdings
CA$42.1b
Through its subsidiaries, provides property and casualty insurance and reinsurance, and investment management services in the United States, Canada, Asia, and internationally.
FRFH.F
CA$1,367.23
7D
2.4%
1Y
53.1%